首页|University of Science and Technology of China Reports Findings in Artificial Int elligence (Antiviral Effectiveness, Clinical Outcomes, and Artificial Intelligen ce Imaging Analysis for Hospitalized COVID-19 Patients Receiving Antivirals)
University of Science and Technology of China Reports Findings in Artificial Int elligence (Antiviral Effectiveness, Clinical Outcomes, and Artificial Intelligen ce Imaging Analysis for Hospitalized COVID-19 Patients Receiving Antivirals)
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
NETL
NSTL
By a News Reporter-Staff News Editor at Robotics & Machine Learning Daily News Daily News-New research on Artificial Intelligenc e is the subject of a report. According to news reporting originating in Hefei, People's Republic of China, by NewsRx journalists, research stated, "There is st ill a lack of clinical evidence comprehensively evaluating the effectiveness of antiviral treatments for COVID-19 hospitalized patients. A retrospective cohort study was conducted at Beijing You'An Hospital, focusing on patients treated wit h nirmatrelvir/ritonavir or azvudine." The news reporters obtained a quote from the research from the University of Sci ence and Technology of China, "The study employed a tripartite analysis-viral dy namics, survival curve analysis, and AI-based radiological analysis of pulmonary CT images-aiming to assess the severity of pneumonia. Of 370 patients treated w ith either nirmatrelvir/ritonavir or azvudine as monotherapy, those in the nirma trelvir/ritonavir group experienced faster viral clearance than those treated wi th azvudine (5.4 days vs. 8.4 days, p <0.001). No significa nt differences were observed in the survival curves between the two drug groups. AI-based radiological analysis revealed that patients in the nirmatrelvir group had more severe pneumonia conditions (infection ratio is 11.1 vs. 5.35, p = 0.0 07). Patients with an infection ratio higher than 9.2 had nearly three times the mortality rate compared to those with an infection ratio lower than 9.2. Our st udy suggests that in real-world studies regarding hospitalized patients with COV ID-19 pneumonia, the antiviral effect of nirmatrelvir/ritonavir is significantly superior to azvudine, but the choice of antiviral agents is not necessarily lin ked to clinical outcomes; the severity of pneumonia at admission is the most imp ortant factor to determine prognosis."
HefeiPeople's Republic of ChinaAsiaAntiinfectivesAntiretroviralsAntiviralsArtificial IntelligenceCOVID-19Clinical MedicineCoronavirusDrugs and TherapiesEmerging TechnologiesHIV Protease InhibitorsHealth and MedicineInfectious DiseaseLung Diseases and ConditionsMachine LearningMortalityPharmaceuticalsPneumoniaPrognosisProtease InhibitorsPulmonologyRNA VirusesRespiratory Tract Diseases and C onditionsRespiratory Tract InfectionsRitonavir TherapySARS-CoV-2Severe A cute Respiratory Syndrome Coronavirus 2ThiazolesViralVirology
NETL
NSTL
